The invention relates to a pharmaceutical including benzyldimethyl(3-[myristoylamino]propyl)ammonium chloride in the monohydrate form or in unhydrated form. The pharmaceutical further comprises dimethyl(3-[myristoylamino]propyl)ammonium oxide and/or dimethyl(3-[myristoylamino]propyl)amine in the appropriate pharmaceutical solvent.